Additional file 1 of Non-insulin-based insulin resistance indexes in predicting atrial fibrillation recurrence following ablation: a retrospective study

Additional file: Figure S1. Receiver operating curve for the use of four insulin resistance indexes in the detection of AF recurrence following ablation. Figure S2. Kaplan–Meier estimated event rates of AF recurrence following ablation according to tertiles of insulin resistance indexes. Figure S3. Kapla-Meier estimated event rates of AF recurrence following ablation according to cut-off values of ROC curves for insulin resistance indexes Figure S4. The calibration plots for the adjusted model predicting AF recurrence. Figure S5. Receiver operating curve for risk factors in the detection of AF recurrence following ablation. Figure S6. Association between TyG index (per 1 unit increase) and AF recurrence following ablation in different subgroups. Figure S7. Association between TG/HDL-C ratio (per 1 unit increase) and AF recurrence following ablation in different subgroups. Figure S8. Restricted cubic spline curves for AF recurrence by METS-IR ans TyG-BMI index after covariate adjustment in DM and non-DM patients. Figure S9. Restricted cubic spline curves for AF recurrence by METS-IR and TyG-BMI index after covariates adjustment in duration of AF ≥ 24 and < 24 months patients. Additional file: Table S1. Association between non-insulin-based IR indexes and AF recurrence after ablation stratified by the statins medication at admission. Table S2. Association between METS-IR or TyG-BMI index with DM or non-DM and AF recurrence after ablation. Table S3. Added predictive ability and reclassification statistics of METS-IR and TyG-BMI index in DM and non-DM patients. Table S4. Association between METS-IR or TyG-BMI index with duration of AF ≥ 24 or < 24months and AF recurrence after ablation. Table S5. Added predictive ability and reclassification statistics of METS-IR and TyG-BMI index in duration of AF ≥ 24 and < 24 months patients

Data_Sheet_1_Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients.docx

AimAdvanced liver fibrosis is independently associated with new onset of atrial fibrillation (AF). Non-invasive liver fibrosis scores are considered an effective strategy for assessing liver fibrosis. This study aimed to investigate the association between advanced liver fibrosis and AF recurrence after ablation in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methodsA total of 345 AF patients with NAFLD who underwent de novo ablation between 2019 and 2020 at two large hospitals in China were included in this study. AF recurrence was defined as the occurrence of atrial arrhythmia for more than 30 s by electrocardiogram or 24 h Holter monitoring after the first 3 months of ablation. Predictive values of non-alcoholic fatty liver disease fibrosis score (NFS) and Fibrosis-4 (FIB-4) scores for AF burden and recurrence after ablation were assessed.ResultsAt the 1 year follow-up after ablation, 38.8% of patients showed recurrence. Patients with recurrence who had higher FIB-4 and NFS scores were more likely to have persistent AF and a duration of AF ≥ 3 years. In Kaplan–Meier analysis, patients with intermediate and high NFS and FIB-4 risk categories had a higher risk of AF recurrence. Compared to patients with the low risk, intermediate and high NFS, and FIB-4 risk were independently associated with AF recurrence in multivariate Cox regression analysis (high risk: NFS, hazard ratio (HR): 3.11, 95% confidence interval (CI): 1.68∼5.76, p ConclusionNFS and FIB-4 scores for advanced liver fibrosis are associated with AF burden. Advanced liver fibrosis is independently associated with AF recurrence following ablation. Advanced liver fibrosis might be meaningful in risk classification for patients after AF ablation.</p